Abingdon Health, the AIM-quoted diagnostics company, reported a 32% rise in Revenue and a narrower loss for its latest financial year in final results published on 13 October 2026. The company has since published its 2026 Annual Report and notice of annual general meeting, announced on 11 November 2026.
What the company does
Abingdon Health specialises in lateral flow diagnostic tests, the rapid test format familiar to many people from the pandemic. It offers contract development and Manufacturing services, helping other companies design, scale up and produce tests, and it also provides regulatory and related support. The company is based in the UK and has been building a presence in the United States, the world's largest market for diagnostics.
Latest developments
International expansion has been a theme of 2026. On 25 September the company marked the official opening of its manufacturing hub in the US, and on 27 May it announced a US tax Credit agreement. In April it was admitted to trading on the OTCQB market in the US, widening access for American investors.
On 29 September 2026 Abingdon announced it had achieved UKAS ISO/IEC 17025 accreditation, an internationally recognised standard for testing and calibration laboratories. Earlier in the year, the company reported the launch of the LVOne stroke test by UpFront Diagnostics in May and gave an update on its Partnership with 4TEEN4 Pharmaceuticals. It also announced earn-out consideration and an issue of Equity in May, and a trading update on 29 July 2026.
Financial and Dividend picture
According to the final results for the year ended 30 June 2026, total revenue increased 32% to £11.3m. Contract development revenue rose 56% to £5.0m, indicating strong Demand for the company's development services. Gross Margin improved to 47.1%.
The loss before tax narrowed to £2.0m from £3.5m in the previous year, and the company said adjusted EBITDA was positive in the second half. Cash and cash equivalents increased to £2.9m at the year end, and £3.2m of equity was raised during the year. As a growing Business that is not yet profitable on a statutory basis, Abingdon does not pay a dividend.
Sector and index context
Abingdon Health is among the healthcare companies in the FTSE AIM All Share Index. After the surge and subsequent collapse in demand for Covid-19 testing, lateral flow specialists have had to rebuild around a broader range of tests, from infectious diseases to cardiac and stroke markers. Contract manufacturers can benefit from demand for decentralised and point-of-care testing, but must compete with larger global outsourcing providers.
Key risks
The company acknowledged short-term delays that affected the first quarter of its new financial year, illustrating how revenue can depend on the timing of customer projects. Abingdon remains loss-making before tax, with a modest cash position, so further fundraising cannot be ruled out. Expansion in the US brings execution and cost risks, and regulatory approvals for customers' tests can take longer than planned.
What to watch next
Management has said it expects continued revenue growth and an improved EBITDA position in the 2027 financial year. The Annual General Meeting will provide an opportunity for an update on trading after the first-quarter delays. Investors will also watch for new contracts at the US manufacturing hub, progress with partners such as UpFront Diagnostics and 4TEEN4 Pharmaceuticals, and whether the second-half positive EBITDA can be sustained across a full year.






Please wait processing your request...